Our studies suggest that ligands that lead to stronger biased interaction of the α2AR subtypes with β-arrestins over spinophilin would be more beneficial for hypertension treatment than traditional ligands that can enhance binding of both proteins to the receptor. This evidence concerns the gene ADORA2A and hypertensive disorder.